In an analysis stratified by serum PSA concentration, prostate cancer risk was decreased in finasteride and alpha-blocker users with PSA⩾4 ng ml−1 (the cut-off value for screen-positive test, i.e., indication for prostate biopsy; Table 4). Here, KLK3 is linked to prostate cancer.